Partial
Partially Aligned
Patient Risk:
Low
Summary
Most pharmacologic/mechanism and capsule dosing/administration details are consistent with the provided label excerpts. However, the label excerpts do not support some formulation/labeling specifics (e.g., oral capsule administration timing for “highly emetogenic” generally beyond cisplatin-based table context) and omit or conflict with certain developer attribution, and include safety/interaction claims that were not fully evaluated due to lack of explicit label citations for those exact statements. Overall alignment is partial.
Category Scores
Accurate Statements
Akynzeo is a combination medication used to prevent chemotherapy-induced nausea and vomiting (CINV).
Supported by Section 1 indications excerpt describing prevention of acute and delayed nausea and vomiting associated with cancer chemotherapy in combination with dexamethasone.
Akynzeo contains netupitant.
Supported by Section 11 DESCRIPTION and Section 1/12 references: AKYNZEO capsules contain 300 mg netupitant.
Akynzeo contains palonosetron.
Supported by Section 11 DESCRIPTION and Section 12.1: AKYNZEO includes palonosetron; capsule strength includes 0.5 mg palonosetron.
Netupitant is a neurokinin-1 (NK1) receptor antagonist.
Supported by Section 12.1: Netupitant is a selective antagonist of NK-1 receptors.
Palonosetron is a serotonin-5-HT3 receptor antagonist.
Supported by Section 12.1: Palonosetron is a 5-HT3 receptor antagonist.
Akynzeo is prescribed to prevent acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy.
Supported by Section 1 indications excerpt for AKYNZEO for injection/injection: prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy; capsules excerpt includes highly emetogenic chemotherapy as an example/including.
Akynzeo is administered as a single oral capsule.
Partially supported: Section 2.1 table indicates dosing as “1 capsule… 1 hour before chemotherapy” and Section 1 indicates capsules are taken; label excerpts do not explicitly say “single oral capsule” as a universal phrasing across regimens, but the table excerpt aligns with one capsule per dose.
Akynzeo is administered approximately one hour before the start of chemotherapy.
Supported by Section 2.1 table excerpt for AKYNZEO capsules: “1 hour before chemotherapy.”
The recommended dose of Akynzeo is 300 mg of netupitant and 0.5 mg of palonosetron.
Supported by Section 11 DESCRIPTION and the capsule dosage strength shown in label excerpts.
Akynzeo is typically given in combination with a corticosteroid, such as dexamethasone.
Supported by Section 1 indications: “indicated in combination with dexamethasone” for both capsules and injections.
Unsupported Statements
Netupitant blocks NK1 receptors, preventing substance P from binding.
Label excerpt provided states netupitant is an NK-1 receptor antagonist but does not explicitly describe preventing substance P binding.
Palonosetron blocks 5-HT3 receptors, preventing serotonin from binding.
Label excerpt provided states palonosetron is a 5-HT3 receptor antagonist but does not explicitly describe preventing serotonin binding.
Akynzeo is administered as a single oral capsule.
Label excerpts show “1 capsule… 1 hour before chemotherapy” in a specific table/regimen context, but do not explicitly state “single oral capsule” as a general administration rule.
Akynzeo was developed by Helsinn Healthcare S.A.
No provided label excerpt includes developer/manufacturer attribution; the provided excerpts only cover labeling sections such as indications, dosing, contraindications, warnings/precautions, interactions, populations, overdose, description, and clinical pharmacology.
Contradictions
Important Omissions
The label excerpt specifies that AKYNZEO capsules are indicated in combination with dexamethasone, and also provides specific timing for dexamethasone relative to chemotherapy (e.g., 8 mg once daily Days 2 to 4, and 12 mg 30 minutes before chemotherapy). The claims did not include these specific dexamethasone regimen details.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Evaluated claims are largely descriptive (indication, composition, mechanism classification, dosing timing/strength) and do not introduce explicit contraindications or dosing beyond supported capsule strength/timing. Some mechanistic statements (substance P/serotonin binding) and developer attribution are unsupported but are unlikely to directly cause unsafe prescribing based on the provided excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Some mechanism statements and developer attribution are not explicitly supported by the provided label excerpts; and the “single oral capsule” phrasing/generalization is not fully explicit in the excerpted label text.
Suggested Improvement
Limit mechanism descriptions to the label-supported antagonist classification (without asserting substance P/serotonin binding prevention) and remove/verify developer attribution. For administration, mirror the label wording from the capsule table (e.g., “1 capsule 1 hour before chemotherapy”) rather than asserting a universal “single oral capsule” rule.